Bipolar Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Bipolar disorder is a persistent and intricate mood disorder characterized by a blend of manic (bipolar mania), hypomanic, and depressive (bipolar depression) episodes, often accompanied by significant subsyndromal symptoms that typically emerge between major mood episodes. These disorders have a multifaceted origin involving genetic predisposition influenced by environmental stressors. Children with parents affected by bipolar disorders face a 4% to 15% risk of developing the condition, while those with parents lacking bipolar disorder have less than a 2% risk. The onset and recurrence of bipolar disorder are often linked to acute stressors, including adverse childhood events, trauma, familial suicide, and sleep disruption. Multiple factors such as biological susceptibility, inflammation in the central and peripheral nervous systems, irregular endocrine and neuronal pathways, and mitochondrial dysfunction inheritance patterns have been implicated in these disorders. There are four distinct types of bipolar disorder, each marked by noticeable shifts in mood, energy levels, and activity:
1. Bipolar I disorder features manic episodes lasting at least 7 days, often accompanied by depressive episodes lasting at least 2 weeks. Rapid cycling involves experiencing four or more episodes of mania or depression within a year.
2. Bipolar II disorder is characterized by recurrent depressive and hypomanic episodes, with hypomania being less severe than the manic episodes seen in bipolar I.
3. Bipolar Disorder Not Otherwise Specified (BP-NOS) is diagnosed when symptoms align with bipolar disorder but do not meet the criteria for either bipolar I or II. These symptoms noticeably deviate from the person’s typical behavior.
4. Cyclothymic disorder, or cyclothymia, involves recurring hypomanic and depressive symptoms that do not reach the intensity or duration of hypomanic or depressive episodes.
Patients typically seek treatment for depression or anxiety, sometimes with mixed features, where they experience concurrent mania and depression. Diagnosis may be delayed as several depressive episodes precede the manifestation of mixed features, mania, or hypomania.
Patients often do not seek care for hypomania, viewing it positively despite potential negative consequences. Physicians must inquire about manic or hypomanic symptoms when patients present with depression. Hypomania and mania can be triggered by shift work, travel across time zones, and seasonal light changes, affecting up to 25% of patients with a seasonal pattern. Increased mortality in patients with bipolar disorder is attributed to both unnatural (suicide and accidents) and natural (cardiovascular disorders, diabetes mellitus, chronic obstructive pulmonary disease, influenza, or pneumonia) causes. Approximately 15%–19% of patients with bipolar disorder die by suicide, with a suicide rate 20–30 times higher than that of the general population. The risk of suicide in bipolar disorder is 1.2 times higher than in major depressive disorder. Suicidal behavior primarily occurs during major depressive episodes, less frequently during mixed-line mania, and rarely during euphoric mania, hypomania, or euthymia. Currently, only three approved agents are available for treatment: OFC, quetiapine (immediate or extended-release), and lurasidone (monotherapy or as an adjunct to lithium or valproate).
• An estimated 4.4% of U.S. adults experience bipolar disorder at some point.

Thelansis’s “Bipolar Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bipolar Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Bipolar Disorder across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Bipolar Disorder Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Bipolar Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Bipolar Disorder, Bipolar Disorder market outlook, Bipolar Disorder competitive landscape, Bipolar Disorder market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)